Controllable Activation of Anticancer Prodrugs in vivo

View Statistics Email Alert RSS Feed

Grant Data
Project Title
Controllable Activation of Anticancer Prodrugs in vivo
Principal Investigator
Professor Kong, Fengming P   (Co-Principal Investigator (Co-PI) (for projects led by other university))
Co-Investigator(s)
Dr Zhu Guangyu   (Project coordinator)
Duration
36
Start Date
2024-06-30
Amount
360000
Conference Title
Controllable Activation of Anticancer Prodrugs in vivo
Keywords
""Radiation Therapy""; ""Tumor Microenvironment""; ""Non-small Cell Lung Cancer""; ""Acquired Resistance""; ""Osimertinib""
Discipline
Allergy/Immunology
Panel
Biology and Medicine (M)
HKU Project Code
C1018-23G
Grant Type
Collaborative Research Fund (CRF) - Group Research Project 2023/2024
Funding Year
2023
Status
On-going
Objectives
a）Investigate how radiotherapy influences the immune environment of the tumor immune microenvironment (TIME) and systemic tumor immune environment (STIE) following resistance to Osimertinib in lung cancer.b）Examine the mechanisms underlying the poor responds to immunotherapy after Osimertinib resistance and assess how radiotherapy may enhance immunotherapy by modulating the immune microenvironment.c)  Identify effective biomarkers within the TIME and STIE both before and after radiotherapy and explore potential molecular therapeutic targets and evaluate their combination with immunotherapy to enhance overall treatment efficacy.